155 related articles for article (PubMed ID: 31725045)
21. Efficacy and safety of weekly nab-paclitaxel plus carboplatin in patients with advanced non-small cell lung cancer.
Satouchi M; Okamoto I; Sakai H; Yamamoto N; Ichinose Y; Ohmatsu H; Nogami N; Takeda K; Mitsudomi T; Kasahara K; Negoro S
Lung Cancer; 2013 Jul; 81(1):97-101. PubMed ID: 23545279
[TBL] [Abstract][Full Text] [Related]
22. Safety and efficacy analysis by histology of weekly nab-paclitaxel in combination with carboplatin as first-line therapy in patients with advanced non-small-cell lung cancer.
Socinski MA; Okamoto I; Hon JK; Hirsh V; Dakhil SR; Page RD; Orsini J; Yamamoto N; Zhang H; Renschler MF
Ann Oncol; 2013 Sep; 24(9):2390-6. PubMed ID: 23842283
[TBL] [Abstract][Full Text] [Related]
23. Neoadjuvant atezolizumab and chemotherapy in patients with resectable non-small-cell lung cancer: an open-label, multicentre, single-arm, phase 2 trial.
Shu CA; Gainor JF; Awad MM; Chiuzan C; Grigg CM; Pabani A; Garofano RF; Stoopler MB; Cheng SK; White A; Lanuti M; D'Ovidio F; Bacchetta M; Sonett JR; Saqi A; Rizvi NA
Lancet Oncol; 2020 Jun; 21(6):786-795. PubMed ID: 32386568
[TBL] [Abstract][Full Text] [Related]
24. A prospective phase II study of carboplatin and nab-paclitaxel in patients with advanced non-small cell lung cancer and concomitant interstitial lung disease (HOT1302).
Asahina H; Oizumi S; Takamura K; Harada T; Harada M; Yokouchi H; Kanazawa K; Fujita Y; Kojima T; Sugaya F; Tanaka H; Honda R; Kikuchi E; Ikari T; Ogi T; Shimizu K; Suzuki M; Konno S; Dosaka-Akita H; Isobe H; Nishimura M;
Lung Cancer; 2019 Dec; 138():65-71. PubMed ID: 31654836
[TBL] [Abstract][Full Text] [Related]
25. Weekly nab-Paclitaxel in Combination With Carboplatin as First-Line Therapy in Patients With Advanced Non-Small-Cell Lung Cancer: Analysis of Safety and Efficacy in Patients With Diabetes.
Hirsh V; Ko A; Pilot R; Renschler MF; Socinski MA
Clin Lung Cancer; 2016 Sep; 17(5):367-374. PubMed ID: 27230605
[TBL] [Abstract][Full Text] [Related]
26. Weekly nab-paclitaxel in combination with carboplatin versus solvent-based paclitaxel plus carboplatin as first-line therapy in patients with advanced non-small-cell lung cancer: final results of a phase III trial.
Socinski MA; Bondarenko I; Karaseva NA; Makhson AM; Vynnychenko I; Okamoto I; Hon JK; Hirsh V; Bhar P; Zhang H; Iglesias JL; Renschler MF
J Clin Oncol; 2012 Jun; 30(17):2055-62. PubMed ID: 22547591
[TBL] [Abstract][Full Text] [Related]
27. Updated Survival Data for a Phase I/II Study of Carboplatin plus Nab-Paclitaxel and Concurrent Radiotherapy in Patients with Locally Advanced Non-Small Cell Lung Cancer.
Tsuchiya-Kawano Y; Sasaki T; Yamaguchi H; Hirano K; Horiike A; Satouchi M; Hosokawa S; Morinaga R; Komiya K; Inoue K; Fujita Y; Toyozawa R; Kimura T; Takahashi K; Nishikawa K; Kishimoto J; Nakanishi Y; Okamoto I
Oncologist; 2020 Jun; 25(6):475-e891. PubMed ID: 31649134
[TBL] [Abstract][Full Text] [Related]
28. A Phase I/II Study of Biweekly Carboplatin and Nab-paclitaxel With Concurrent Radiotherapy for Patients With Locally Advanced Unresectable Stage III Non-small-cell Lung Cancer.
Tanaka H; Hasegawa Y; Makiguchi T; Okumura F; Tabe C; Shiratori T; Ishioka Y; Itoga M; Taima K; Yokouchi J; Hatayama Y; Aoki M; Tasaka S
Clin Lung Cancer; 2021 Jan; 22(1):42-48. PubMed ID: 33158764
[TBL] [Abstract][Full Text] [Related]
29. Long term follow-up of neoadjuvant-adjuvant combination treatment of IIIA stage non-small-cell-lung cancer: results of neoadjuvant carboplatin/vinorelbine and carboplatin/paclitaxel regimens combined with selective adjuvant chemotherapy according to in-vitro chemoresistance test.
Kolek V; Grygarkova I; Hajduch M; Klein J; Cwiertka K; Neoral C; Langova K; Mihal V
Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2008 Dec; 152(2):259-66. PubMed ID: 19219217
[TBL] [Abstract][Full Text] [Related]
30. Should patients with stage IB non-small cell lung cancer receive adjuvant chemotherapy? A comparison of survival between the 8th and 7th editions of the AJCC TNM staging system for stage IB patients.
Wang J; Wu N; Lv C; Yan S; Yang Y
J Cancer Res Clin Oncol; 2019 Feb; 145(2):463-469. PubMed ID: 30474757
[TBL] [Abstract][Full Text] [Related]
31. Feasibility of adjuvant chemotherapy with S-1 plus carboplatin followed by single-agent maintenance therapy with S-1 for completely resected non-small-cell lung cancer: results of the Setouchi Lung Cancer Group Study 1001.
Okumura N; Sonobe M; Okabe K; Nakamura H; Kataoka M; Yamashita M; Nakata M; Kataoka K; Yamashita Y; Soh J; Yoshioka H; Hotta K; Matsuo K; Sakamoto J; Toyooka S; Date H
Int J Clin Oncol; 2017 Apr; 22(2):274-282. PubMed ID: 27921177
[TBL] [Abstract][Full Text] [Related]
32. Pathologic response after neoadjuvant carboplatin and weekly paclitaxel for early-stage lung cancer: a Brown University oncology group phase II study.
Ahmed S; Birnbaum AE; Safran HP; Dipetrillo TA; Aswad BI; Ready NE; Ng T
J Thorac Oncol; 2011 Aug; 6(8):1432-4. PubMed ID: 21847062
[TBL] [Abstract][Full Text] [Related]
33. Phase II trial of postoperative adjuvant paclitaxel/carboplatin and thoracic radiotherapy in resected stage II and IIIA non-small-cell lung cancer: promising long-term results of the Radiation Therapy Oncology Group--RTOG 9705.
Bradley JD; Paulus R; Graham MV; Ettinger DS; Johnstone DW; Pilepich MV; Machtay M; Komaki R; Atkins J; Curran WJ;
J Clin Oncol; 2005 May; 23(15):3480-7. PubMed ID: 15908657
[TBL] [Abstract][Full Text] [Related]
34. nab-Paclitaxel in Combination With Weekly Carboplatin With Concurrent Radiotherapy in Stage III Non-Small Cell Lung Cancer.
Lammers PE; Lu B; Horn L; Shyr Y; Keedy V
Oncologist; 2015 May; 20(5):491-2. PubMed ID: 25845992
[TBL] [Abstract][Full Text] [Related]
35. Phase I study of weekly nab-paclitaxel plus carboplatin and concurrent thoracic radiotherapy in elderly patients with unresectable locally advanced non-small cell lung cancer.
Omori S; Harada H; Mori K; Hisamatsu Y; Tsuboguchi Y; Yoshioka H; Morinaga R; Daga H; Kurata T; Takahashi T
Invest New Drugs; 2022 Feb; 40(1):106-114. PubMed ID: 34495421
[TBL] [Abstract][Full Text] [Related]
36. Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial.
West H; McCleod M; Hussein M; Morabito A; Rittmeyer A; Conter HJ; Kopp HG; Daniel D; McCune S; Mekhail T; Zer A; Reinmuth N; Sadiq A; Sandler A; Lin W; Ochi Lohmann T; Archer V; Wang L; Kowanetz M; Cappuzzo F
Lancet Oncol; 2019 Jul; 20(7):924-937. PubMed ID: 31122901
[TBL] [Abstract][Full Text] [Related]
37. A Randomized Phase III Study Comparing Carboplatin With Nab-Paclitaxel Versus Docetaxel for Elderly Patients With Squamous-Cell Lung Cancer: Study Protocol.
Kogure Y; Saka H; Takiguchi Y; Atagi S; Kurata T; Ebi N; Inoue A; Kubota K; Takenoyama M; Seto T; Kada A; Yamanaka T; Ando M; Yamamoto N; Gemma A; Ichinose Y
Clin Lung Cancer; 2018 Sep; 19(5):e711-e715. PubMed ID: 29861395
[TBL] [Abstract][Full Text] [Related]
38. Phase I/II study of carboplatin plus nab-paclitaxel and concurrent radiotherapy for patients with locally advanced non-small cell lung cancer.
Kawano Y; Sasaki T; Yamaguchi H; Hirano K; Horiike A; Satouchi M; Hosokawa S; Morinaga R; Komiya K; Inoue K; Fujita Y; Toyozawa R; Kimura T; Takahashi K; Nishikawa K; Kishimoto J; Nakanishi Y; Okamoto I
Lung Cancer; 2018 Nov; 125():136-141. PubMed ID: 30429011
[TBL] [Abstract][Full Text] [Related]
39. nab-Paclitaxel/carboplatin in elderly patients with advanced squamous non-small cell lung cancer: a retrospective analysis of a Phase III trial.
Gridelli C; Chen T; Ko A; O'Brien ME; Ong TJ; Socinski MA; Postmus PE
Drug Des Devel Ther; 2018; 12():1445-1451. PubMed ID: 29872267
[TBL] [Abstract][Full Text] [Related]
40. Second-line, low-dose, weekly paclitaxel in patients with stage IIIB/IV nonsmall cell lung carcinoma who fail first-line chemotherapy with carboplatin plus paclitaxel.
Socinski MA; Schell MJ; Bakri K; Peterman A; Lee JH; Unger P; Yates S; Hudgens S; Kies MS
Cancer; 2002 Sep; 95(6):1265-73. PubMed ID: 12216094
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
